首页 | 官方网站   微博 | 高级检索  
     


Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2? Advanced Breast Cancer
Authors:Matthew P Goetz  Miguel Martin  Eriko Tokunaga  In Hae Park  Jens Huober  Masakazu Toi  Clemens Stoffregen  Sarah Shekarriz  Valerie Andre  M Corona Gainford  Gregory L Price  Stephen Johnston
Affiliation:1. Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA;2. Instituto de Investigacion Sanitaria Gregorio Marañon, Ciberonc, Geicam, Universidad Complutense, Madrid, Spain;3. National Hospital Organization, Kyushu Cancer Center, Fukuoka, Japan;4. National Cancer Center, Gyeonggi-Do, Republic of South Korea;5. Breast Center, Universitätsklinikum Ulm, Ulm, Germany;6. Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan;7. Eli Lilly & Co., Bad Homburg, Germany;8. Eli Lilly & Co., Paris, France;9. Eli Lilly & Co., Indianapolis, Indiana, USA;10. The Royal Marsden NHS Foundation Trust, London, United Kingdom
Abstract:
Keywords:Abemaciclib  Advanced breast cancer  Cyclin-dependent kinase 4/6 inhibitor  Health-related quality of life  Patient-reported outcomes
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号